Sigma announces the addition of new Prestige Antibodies powered by Atlas Antibodies, bringing total to over 10,000

Effort is key part of Sweden’s Human Protein Atlas (HPA) project, which aims to develop at least one antibody to all non-redundant human proteins by 2015

Register for free to listen to this article
Listen with Speechify
ST. LOUIS—Reaching a key milestone in an exclusive partnership with Atlas Antibodies AB to develop the Human Protein Atlas (HPA) project, Sigma Life Science, the biological products and services business of Sigma-Aldrich, has announced the introduction of 1,700 new products to its collection of highly characterized Prestige Antibodies. With this addition, the entire portfolio (available at now includes more than 10,000 antibodies and covers 8,400 protein targets.

"A milestone in the Human Protein Atlas project has now been reached with the inclusion of more than 10,000 human protein-coding genes," says Professor Mathias Uhlén of the Royal Institute of Technology (KTH) in Stockholm, Sweden. "With this new version of the Human Protein Atlas, we have moved toward a knowledge­based portal, with gene-centric expression profiles based on the annotation of several antibodies toward the same target."

Each Prestige Antibody is supported by more than 700 immunohistochemistry, immunofluorescence and Western blot images, with complete data for each product publicly available through the HPA, the partners note. The continued expansion of this collection is part of the Sweden's HPA project, which aims to develop at least one antibody to all non-redundant human proteins by 2015.

"The addition of these new Prestige Antibodies expands Sigma's antibody portfolio, providing researchers with reliable antibody products for more protein targets and more applications," notes Becki Davis, product manager for antibodies at Sigma Life Science, who adds that the company's complete collection of more than 40,000 world-class antibodies, including the Prestige Antibody portfolio, are included in the company's new searchable Antibody Explorer database, "helping scientists to find the right product for their needs and accelerating our fundamental understanding of biology."

Sigma-Aldrich's chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology and pharmaceutical development, and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The company has customers in life science companies, university and government institutions, hospitals, and in industry, with more than a million scientists and technologists repoprtedly using its products. Sigma-Aldrich operates in 40 countries and has 7,700 employees.

Atlas Antibodies was founded in 2006 by researchers at the Royal Institute of Technology, the Rudbeck Laboratory and Uppsala University in Uppsala, Sweden. Atlas Antibodies manufactures, markets and sells the antibody products developed and characterized within the HPA project. Atlas Antibodies also has exclusive right to patent and commercialize biomarkers discovered by the HPA project, which is performing a systematic exploration of the human proteome with antibody-based proteomics, combining high-throughput generation of affinity-purified polyclonal antibodies with protein profiling using tissue microarrays.
The HPA project generates expression and localization patterns of proteins in a large portion of both normal and cancer human tissues and organs resulting in the antibody-based profiling presented via the publicly available Human Protein Atlas portal. The HPA vision is to "enable the systematic generation of quality assured antibodies to all non-redundant human proteins and to use these reagents to functionally explore human proteins, protein variants and protein interactions."

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue